Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03014622 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines
A Phase 3 study, sponsored by Revance Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 303
- Enrollment target
NCT03014622 is a Phase 3 study that has completed, run by Revance Therapeutics. The registered enrollment target is 303 participants.
The verdict
NCT03014622, a Phase 3 study, has completed, sponsored by Revance Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 303 participants
- Enrollment target
Study Summary
This is a safety and efficacy study of DaxibotulinumtoxinA for Injection to treat moderate to severe frown lines.
Interventions
- BIOLOGICAL Botulinum Toxins, Type A
- BIOLOGICAL Placebos
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 303 participants |
| Start Date | 2016-12-08 |
| Est. Completion | 2017-11-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03014622
The ClinicalTrials.gov registry entry for NCT03014622 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 303 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Revance Therapeutics, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Botulinum Toxins, Type A is the first listed.
NCT03014622 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03014622 about?
NCT03014622 is a clinical study titled "Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines". This is a safety and efficacy study of DaxibotulinumtoxinA for Injection to treat moderate to severe frown lines.
What is the current status of trial NCT03014622?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 303 participants. The study started on 2016-12-08. Estimated completion is 2017-11-14.
What interventions are being tested in trial NCT03014622?
The interventions under investigation include: Botulinum Toxins, Type A (BIOLOGICAL), Placebos (BIOLOGICAL).
Who is sponsoring clinical trial NCT03014622?
This trial is sponsored by Revance Therapeutics, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.